AnaptysBio (NASDAQ:ANAB) Rating Increased to Hold at Truist Financial

Truist Financial upgraded shares of AnaptysBio (NASDAQ:ANAB) to a hold rating in a research note released on Wednesday,Zacks.com reports.

ANAB has been the topic of several other reports. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Stifel Nicolaus upped their price objective on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Barclays raised their target price on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Finally, Wedbush upped their price target on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $78.44.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $65.39 on Wednesday. The company’s 50 day simple moving average is $54.69 and its 200 day simple moving average is $43.09. AnaptysBio has a fifty-two week low of $15.40 and a fifty-two week high of $68.39. The firm has a market capitalization of $1.88 billion, a P/E ratio of -125.75 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Sell-side analysts expect that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the transaction, the director directly owned 9,930 shares in the company, valued at approximately $478,923.90. The trade was a 52.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Faga sold 14,281 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $638,503.51. Following the completion of the transaction, the chief executive officer directly owned 479,344 shares of the company’s stock, valued at approximately $21,431,470.24. The trade was a 2.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 92,514 shares of company stock worth $4,243,935 over the last 90 days. 33.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after purchasing an additional 67,048 shares during the period. State Street Corp increased its stake in AnaptysBio by 20.6% during the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after purchasing an additional 180,042 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after buying an additional 822,975 shares during the period. 683 Capital Management LLC raised its holdings in AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 101,093 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in AnaptysBio in the fourth quarter valued at approximately $21,559,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.